Abstract: The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis. In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.

Abstract: The present disclosure relates to the field of microbial technology, and discloses a probiotic composition and use thereof. The probiotic composition in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering epididymal fat content, lowering fasting blood glucose level, lowering the area under sugar tolerance curve and lowering contents of serum low density lipoprotein and total cholesterol, improving liver antioxidant capacity and lowering serum IL-1? content, etc. The extent of decrease or increase is increased by 9.62% to 769.62% compared with formulations of a single probiotic or a combination of two probiotics. The combination of three probiotics achieves a significant synergistic effect.

Abstract: The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.

Abstract: The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.

Abstract: The present invention relates to a combination of experimental and computational workflows that allow characterization of specific molecular mechanisms by which the microbiome contribute to skin health and skin age.

Abstract: The present invention relates to a composition comprising a given Lactobacillus rhamnosus strain and a given Lactobacillus paracasei strain wherein the ratio of the given Lactobacillus rhamnosus strain to the given Lactobacillus paracasei strain (LR?:LP?) is higher or equal to 8:1 and to methods thereof.

Abstract: Provided is a method of producing an oil containing polyunsaturated fatty acids by using Schizochytrium sp. The method comprises: performing fermentation using Schizochytrium sp.; resuspending the resultant cells after fermentation in water, adding cellulase and neutral protease for enzymolysis; mixing the enzymatic hydrolyzate with n-hexane, shaking, extracting, centrifuging, and collecting the n-hexane phase; concentrating the n-hexane phase under reduced pressure to remove the n-hexane, and drying to obtain an oil; performing a first crystallization and a second crystallization, and then performing cold filtration to obtain a liquid oil after the second crystallization; and subjecting the liquid oil to deacidification and decolorization. By regulating fermentation conditions and conducting concentration processing on polyunsaturated fatty acids, the content of eicosapentaenoic acid in the Schizochytrium sp.

Abstract: The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.

Abstract: Methods for controlling the growth of microorganisms in or on a product, material, or medium, such as a fermentable or fermenting medium, susceptible to attack by a microorganism, by treating with aqueous solution comprising monochloramine and at least one organic acid in a synergistically microbicidally effective combined amount to control unwanted microbial growth. Microbicidal aqueous solutions containing monochloramine and at least one organic acid in a synergistically microbicidally effective combined amount to control the growth of at least one microorganism are also described.

Abstract: Hygienic Hydrophilic coatings, hydrophilic coating formulations and wetting fluids that include an anti-infective agent.

Abstract: The present invention relates to at least one probiotic strain of Lactobacillus for use in a subject for the prevention and/or treatment of celiac disease autoimmunity (CDA), or for use in the prevention and/or treatment of celiac disease (CD). A preferred composition for use according to the invention is a composition comprising a combination of Lactobacillus paracasei and Lactobacillus plantarum, especially L. paracasei 8700:2 (DSM 13434) in combination with L. plantarum HEAL 9 (DSM 15312).

Abstract: A method for efficiently producing PHA comprising: inoculating PHA fermentation strains into a fermentation medium for fermentation under the condition of being capable of producing PHA through fermentation; subjecting the fermentation broth to a solid-liquid separation to obtain fermentation supernatant and thallus precipitate; breaking the cell walls of the thallus precipitate, and subjecting the wall-broken products to a plate and frame filtration to prepare PHA; pre-coating a filter cloth for the plate and frame filtration with a PHA layer; at least part of the water of the fermentation medium is PHA process wastewater. The method utilizes the PHA process wastewater as at least part of the water of the fermentation medium, and filters and separates the broken thallus with the plate and frame filtration equipment pre-coated with PHA layer to prepare PHA, thereby recycling the high-salt wastewater, reducing costs, and potentially separating PHA on a large scale for industrial production.

Abstract: An assay is performed so as to identify a pathogen in a sample taken from a patient. The identity of the pathogen in the patient sample is used to select an antimicrobial for treatment of the patient. The antimicrobial can be selected in less than 7 hours after the patient sample is taken from the patient. For instance, when the sample is blood, the antimicrobial can be selected in less than 7 hours after the patient sample is taken from the patient. When the sample is urine, the antimicrobial can be selected in less than 4 hours after the patient sample is taken from the patient.

Abstract: Methods and compositions for long term continuous flow fermentation using a two vessel continuous culture fermentation apparatus are described.

Abstract: The present invention provides anallergic compositions, including food products, comprising probiotic bacterial cultures including probiotic strains of Lactobacillus, Bifidobacterium, Lactococcus, Streptococcus, and/or Staphylococcus.

Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells. Provided herein are a population of oligodendrocyte progenitor cells (OPCs) derived from pluripotent stem cells, methods of generating the same for use in the treatment of acute spinal cord injury and other conditions affecting the CNS, and containers including the population of OPCs.

Abstract: A catalyst having a porous support having at least one of thermally or electrically conductive particles bonded by a polymer, and enzymes embedded into pores of the porous support. A process of manufacturing an enzyme-embedded porous support includes forming solution of monomers, enzymes, a solvent, and at least one of electrically and thermally conductive particles, polymerizing the monomers by adding initiators to the solution, and evaporating the solvent to produce an enzyme-embedded porous support. A process of manufacturing an enzyme embedded porous support, includes mixing enzymes, at least one of electrically conductive or thermally conductive particles, and a polymer in a solvent, and evaporating the solvent.

Abstract: The present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing Lactobacillus reuterii bacteria as a probiotic to reduce weight gain or to induce weight loss, particularly for subjects receiving an antibiotic or xenobiotic treatment.

Abstract: Protein-rich nutrient supplements and animal feed supplements derived from an anaerobic bacterial process are generated through a myriad of cell rupturing and protein fractionation/purification processes. Bacterial fermentation systems and methods of obtaining one or more protein-containing portions from a fermentation process using carbon monoxide-containing gaseous substrates are provided. The invention further provides compositions of protein-rich nutrient supplements with useful applications for intake by a variety of different animals and humans.

Abstract: The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.